<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127772">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01931475</url>
  </required_header>
  <id_info>
    <org_study_id>13494</org_study_id>
    <secondary_id>F1J-MC-HMGS</secondary_id>
    <nct_id>NCT01931475</nct_id>
  </id_info>
  <brief_title>A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China</brief_title>
  <official_title>Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of duloxetine once daily
      compared with placebo on the reduction of pain due to osteoarthritis (OA) in knee or hip in
      participants in China.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change from Baseline to 13 Weeks in the Brief Pain Inventory (BPI) 24-hour Average Pain Rating</measure>
    <time_frame>Baseline, 13 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impressions of Improvement (PGI-I) at 13 Weeks</measure>
    <time_frame>13 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 13 Weeks in Western Ontario and McMaster Universities Arthritis Index (WOMAC) Total and Subscale Scores</measure>
    <time_frame>Baseline, 13 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 13 Weeks in Clinical Global Impression of Severity (CGI-S)</measure>
    <time_frame>Baseline, 13 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 13 Weeks in BPI Severity</measure>
    <time_frame>Baseline, 13 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline to 13 Weeks in Hospital Anxiety and Depression Scale-Depression (HADS-D) or HADS-Anxiety (HADS-A) Subscale Scores</measure>
    <time_frame>Baseline, 13 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting dose is 30 milligram (mg) duloxetine, then titrate up to 60 mg administered daily by mouth for about 27 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matches the duloxetine capsule. After 13 weeks administered daily by mouth, then change to duloxetine administered daily by mouth for about 14 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meet clinical and radiographic criteria for the diagnosis of OA of the knee or hip
             with pain for ≥14 days of each month for 3 months prior to study entry

          -  Have a rating ≥4 on the Brief Pain Inventory (BPI) 24-hour average pain item
             (Question 3 of the BPI modified short form) at both Screening and Randomization

        Exclusion Criteria:

          -  Have previously completed/withdrawn from this study or any other study investigating
             duloxetine (Note: Participants who have been previously screened for a duloxetine
             study other than this study and never received investigational product will be
             eligible for this study if they meet all current entry criteria)

          -  Have had previous exposure to duloxetine

          -  Have any previous diagnosis of psychosis, bipolar disorder, or schizoaffective
             disorder

          -  Current (within 1 year of Screening) Diagnostic and Statistical Manual of Mental
             Disorders, Fourth Edition Axis I diagnosis of major depressive disorder, anxiety
             disorders (excluding phobias), alcohol or eating disorders, as determined by the
             Mini-International Neuropsychiatric Interview or a previous diagnosis

          -  Have a history of substance abuse or dependence within the past year, excluding
             nicotine and caffeine

          -  Are taking any excluded medications that cannot be discontinued at Screening

          -  Have had treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of
             randomization or the potential need to use an MAOI during the study or within 5 days
             of discontinuation of investigational product

          -  Have a positive urine drug screen for any substance of abuse or excluded medication

          -  Have serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or
             other medical or psychiatric condition that, in the opinion of the investigator,
             would compromise participation or be likely to lead to hospitalization during the
             course of the study

          -  Have a history of recurrent seizures other than febrile seizures

          -  Are judged clinically by the investigator to be at suicidal risk according to the
             Columbia - Suicide Severity Rating Scale (C-SSRS): a &quot;Yes&quot; answer to either Question
             4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or
             Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the&quot;Suicidal
             Ideation&quot; portion of the C-SSRS or a &quot;Yes&quot; answer to any of the suicide related
             behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act or
             behavior) on the &quot;Suicidal Behavior&quot; portion of the C-SSRS, with the
             ideation/behavior having occurred within the previous month

          -  Have uncontrolled narrow-angle glaucoma

          -  Have acute liver injury (such as hepatitis) or severe

          -  Have known hypersensitivity to duloxetine or any of the inactive ingredients or have
             frequent/severe allergic reactions to multiple medications

          -  Have frequent falls that could result in hospitalization or could compromise response
             to treatment

          -  Have a diagnosis of inflammatory arthritis [that is, rheumatoid arthritis (RA)] or an
             autoimmune disorder (excluding inactive Hashimoto's thyroiditis)

          -  Have received intra-articular hyaluronate/steroids, joint lavage, or other invasive
             therapies to the index joint in the previous 3 months

          -  Have had arthroscopy of the index joint within the previous year or joint replacement
             of the index joint at any time

          -  Have surgery of the index joint scheduled to occur during the trial or are
             anticipated by the investigator to require surgery for the treatment of the OA of the
             index hip or knee along the duration of the study

          -  Have had a prior synovial fluid analysis showing a white blood cell (WBC) count
             ≥2000 cubic millimeter (mm3) that is indicative of a diagnosis other than OA

          -  Are non-ambulatory or require the use of crutches or a walker

          -  Have a body mass index &gt;40

          -  Are anticipated by the investigator to require use of analgesic agents including, but
             not limited to, nonsteroidal anti-inflammatory drugs (NSAIDs),
             acetaminophen/paracetamol, and opioids, or other excluded medication for the duration
             of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM-5PM Eastern Time (UTC/GMT-5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eil Lilly</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bengbu</city>
        <zip>233004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changchun</city>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chengdu</city>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guang Zhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pingxiang</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shenyang</city>
        <zip>110016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>August 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Duloxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
